Know Where Your Product Stands: MDR Readiness & Risk for Health Products
Why Early MDR Clarity Is a Strategic Advantage
When the MDR becomes a key issue, the stakes are already high. Your product has features, claims and users, all of which carry regulatory weight. Adding a feature can change your classification without warning. Taking a defensible position protects your roadmap and investors.
Unintentional Classification
- A wellness app that tracks symptoms can qualify as a medical device
- Intended use and claims matter more than product category
- Many teams only discover this during due diligence or funding rounds
Changes Trigger Reclassification
- Adding a risk score or clinical recommendation shifts the MDR class
- A single UI change can move classification from Class I to Class IIa
- Reclassification mid-development is expensive and disruptive
AI Features Carry Regulatory Weight
- AI-generated outputs that influence clinical decisions are MDR-relevant
- Summarisation of patient data is not automatically outside MDR scope
- The regulatory impact depends on what the output is used for
Clarity Now and Fewer Problems
- Late regulatory discovery forces costly redesigns and delays
- Investors and partners increasingly ask about MDR status early
- Knowing the own position enables to build with confidence and speed
Our MDR Risk & Readiness Deep Dive for Health Products in 3 Steps
1. Structured Preparation Before the Day
You share a detailed briefing package ahead of the session: intended use, system boundaries, feature overview and open regulatory questions. We analyse this before we start and arrive prepared to go deep.
2. A Full Day of Structured MDR Analysis
Over the course of a full day we work through your claims: language, feature-level exposure risks, AI and automation outputs, user workflow context and classification logic. We build your MDR position from the ground up.
3. Position Paper Followed by an Alignment Call
You will receive a written classification paper within 2–3 days. This will contain your MDR stance, full risk register and prioritised action plan. We will then talk your team through it to ensure they understand the findings.
Included in the MDR Risk & Readiness Deep Dive for Health Products?
A full-day structured assessment with a formal written output and a follow-up alignment call. Here is exactly what you get for 2,900 €.
What's Included:
- Defendable MDR classification position
- Full intended use and marketing claims review
- Feature-level MDR exposure risk register
- AI output and automation regulatory analysis
- Structured action plan with priorities
- Written classification position paper for investors and partners
- Alignment walking through findings and defining the regulatory roadmap
How It Works:
You share a briefing package ahead of the session: intended use, system boundaries, feature overview and open questions.
Full day structured deep-dive session: detailed review of claims, functionality, user context and regulatory exposure.
Expert classification position paper delivered within 2–3 days.
Follow-up alignment call: walk through findings and define next steps
At a Glance:
1 Day + Remote + 2,900 €
Book Your MDR Risk & Readiness Deep Dive
See Our MDR based Development
Success Stories
Clients About the MDR Risk & Readiness Dive for Health Products
Asterisk
Veronica Kirin, Founder & CEO
Imaginary
Lucia Pannese, CEO
Natal Mind
Aura Pyykönen, MD PhD
Your Guides for the Health Product MDR Risk & Readiness Deep Dive
Josua Ziegler
CEO
10 years of experience in startup and corporate strategy consulting.
Led digital transformation projects across health, finance and sports in Europe and Middle East.
Christopher Taylor
Sr. Product Manager
Over 10 years experience in product and project management.
Led multiple startup and enterprise-level products in emerging technologies such as AI, automation and VR.
Clients We’ve Already Worked With
FAQs for the MDR Risk & Readiness Deep Dive for Healthcare Products
Q1: What exactly is the MDR Risk & Readiness Deep Dive for Health Products?
A1: It is a full-day structured MDR assessment that delivers a defendable classification position, a feature-level exposure risk register and a prioritised regulatory action plan. It includes a formal written position paper and a follow-up alignment call, all at a fixed price of 2,900 €.
Q2: Who is this MDR Risk & Readiness Deep Dive for Health Products designed for?
A2: It is designed for digital health teams who have a working product or demo, a draft intended use and an active regulatory question. If you already know MDR is relevant but need a clear, documented position, this is the right next step.
Q3: How is this different from the MDR Triage Sprint?
A3: The Triage Sprint answers one question: Are you MDR-relevant? The mDR Risk & Readiness Deep Dive for Health Products goes further. It builds a full classification position using Rule 11, maps your feature-level exposure in detail, analyses your AI and automation outputs and delivers a formal position paper you can use externally. It is the right choice when you need more than a directional answer.
Q4: What triggers MDR reclassification for an existing healthcare product?
A4: Reclassification is most commonly triggered by changes to intended use language, the addition of features that produce patient-specific outputs, AI-generated recommendations that influence clinical decisions and shifts in the user workflow context. Small changes that seem cosmetic can have significant regulatory consequences.
Q5: What does the classification position paper include?
A5: It includes your formal MDR stance, a structured risk register of your feature-level exposure signals, an analysis of your AI and automation outputs and a prioritised action plan with clear next steps. It is written to be shareable with investors, partners and future Notified Body conversations.
Q6: What are the typical next steps after the MDR Risk & Readiness Deep Dive for Healthcare Products?
A6: For products approaching launch, the most common next step is a Full MDR Risk Assessment, which delivers a formal intended use definition, MDR rule-based classification and a structured assessment report. For confirmed Class I+ devices, MDR Implementation and QMS Setup becomes relevant.
Q7: Can the position paper be used in investor or partner conversations?
A7: Yes. The position paper is specifically designed to be shareable. It gives investors and partners a documented, defensible view of your regulatory position including your classification rationale, known risk areas and the steps you are taking to address them. In digital health due diligence, this level of preparation increasingly determines whether conversations move forward.
